Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
7.05% $44.93
America/New_York / 25 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 2 600.47 mill |
EPS: | -3.00 |
P/E: | -14.98 |
Earnings Date: | May 02, 2024 |
SharesOutstanding: | 57.88 mill |
Avg Daily Volume: | 0.582 mill |
RATING 2024-04-25 |
---|
C+ |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -14.98 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-2.55x |
Company: PE -14.98 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$-14.24 (-131.70%) $-59.17 |
Date: 2024-04-26 |
Expected Trading Range (DAY) |
---|
$ 43.17 - 46.69 ( +/- 3.92%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-19 | Shuman Harry | Sell | 115 | Common Shares |
2023-12-15 | Silverman Peter B. | Buy | 1 286 | Common Shares |
2023-12-15 | Silverman Peter B. | Buy | 21 100 | Common Shares |
2023-12-15 | Silverman Peter B. | Sell | 21 100 | Share Option (right to buy) |
2023-12-15 | Silverman Peter B. | Sell | 22 386 | Common Shares |
INSIDER POWER |
---|
69.33 |
Last 99 transactions |
Buy: 2 523 001 | Sell: 3 636 553 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $44.93 (7.05% ) |
Volume | 1.913 mill |
Avg. Vol. | 0.582 mill |
% of Avg. Vol | 328.81 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:34 | buy | $40.33 | N/A | Active |
---|
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.